Open Access
CC BY-NC-ND 4.0 · Geburtshilfe Frauenheilkd 2021; 81(05): 539-548
DOI: 10.1055/a-1464-1221
GebFra Science
Review/Übersicht

Update Breast Cancer 2021 Part 2 – Advanced Stages, Long-Term Consequences and Biomarkers

Artikel in mehreren Sprachen: English | deutsch
Nina Ditsch
1   Department of Gynecology and Obstetrics, University Hospital Augsburg, Augsburg, Germany
,
Elmar Stickeler
2   Department of Gynecology and Obstetrics, RWTH University Hospital Aachen, Aachen, Germany
,
Annika Behrens
3   Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
,
Erik Belleville
4   ClinSol GmbH & Co. KG, Würzburg, Germany
,
Peter A. Fasching
3   Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
,
Tanja N. Fehm
5   Department of Gynecology and Obstetrics, University Hospital Düsseldorf, Düsseldorf, Germany
,
Andreas D. Hartkopf
6   Department of Obstetrics and Gynecology, University of Tübingen, Tübingen, Germany
,
Christian Jackisch
7   Department of Obstetrics and Gynecology, Sana Klinikum Offenbach, Offenbach, Germany
,
Wolfgang Janni
8   Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany
,
Cornelia Kolberg-Liedtke
9   Department of Gynecology and Obstetrics, University Hospital Essen, Essen, Germany
,
Hans-Christian Kolberg
10   Department of Gynecology and Obstetrics, Marienhospital Bottrop, Bottrop, Germany
,
Diana Lüftner
11   Charité University Hospital, Department of Hematology, Oncology and Tumour Immunology, University Medicine Berlin, Berlin, Germany
,
Michael P. Lux
12   Klinik für Gynäkologie und Geburtshilfe, Frauenklinik St. Louise, Paderborn, St. Josefs-Krankenhaus, Salzkotten, St. Vincenz Krankenhaus GmbH, Paderborn, Germany
,
Volkmar Müller
13   Department of Gynecology, Hamburg-Eppendorf University Medical Center, Hamburg, Germany
,
Andreas Schneeweiss
14   National Center for Tumor Diseases (NCT), Heidelberg University Hospital and German Cancer Research Center, Heidelberg, Germany
,
Florian Schütz
15   Gynäkologie und Geburtshilfe, Diakonissen-Stiftungs-Krankenhaus Speyer, Speyer, Germany
,
Carla E. Schulmeyer
3   Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
,
Hans Tesch
16   Oncology Practice at Bethanien Hospital Frankfurt, Frankfurt, Germany
,
Christoph Thomssen
17   Department of Gynaecology, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany
,
Christoph Uleer
18   Praxisgemeinschaft Frauenärzte am Bahnhofsplatz, Hildesheim, Germany
,
Michael Untch
19   Clinic for Gynecology and Obstetrics, Breast Cancer Center, Genecologic Oncology Center, Helios Klinikum Berlin Buch, Berlin, Germany
,
Manfred Welslau
20   Onkologie Aschaffenburg, Aschaffenburg, Germany
,
Achim Wöckel
21   Department of Gynecology and Obstetrics, University Hospital Würzburg, Würzburg, Germany
,
Lena A. Wurmthaler
3   Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
,
Rachel Würstlein
22   Breast Center, Department of Gynecology and Obstetrics and CCC Munich Ludwig Maximilians University, LMU University Hospital, Munich, Germany
,
Marc Thill
23   Agaplesion Markus Krankenhaus, Department of Gynecology and Gynecological Oncology, Frankfurt, Germany
,
Bahriye Aktas
24   Klinik und Poliklinik für Gynäkologie, Universitätsklinikum Leipzig, Leipzig, Germany
› Institutsangaben
Preview

Abstract

This review summarises and discusses significant aspects of recently published studies on patient treatment in advanced breast cancer and on biomarkers in breast cancer. In recent years, a large number of drugs for all molecular subtypes have been developed up to phase III trials. With regard to immune checkpoint inhibitors in metastasised breast cancer, the recent discussion has centred on the best candidate for combined chemotherapy. The oral taxanes could become a new type of oral chemotherapies. There is a growing body of data on biomarkers for the use of CDK4/6 inhibitors, which could also signify further development for other molecular subtypes. New substances have been developed for metastatic HER2+ breast cancer that still result in good remission even after massive prior treatment and/or cerebral metastasis. Similarly, knowledge is growing about targeted therapies with antibody-drug conjugates (ADC) against Trop-2, which could bolster our therapeutic armoury in triple-negative breast cancer (TNBC). In addition, the clinical focus is on understanding how to maintain fertility after breast cancer treatment. Here, pooled analyses provide new insights.



Publikationsverlauf

Eingereicht: 17. März 2021

Angenommen nach Revision: 23. März 2021

Artikel online veröffentlicht:
03. Mai 2021

© 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany